Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
← catalyst calendarNCT06987695 · readout in 251 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
279actual
Sites
30
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-13 | actual | When the study began enrolling |
| Primary completion | 2027-04-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity Disease
Interventions
- Drug: Maridebart cafraglutide — also filed as AMG 133, MariTide
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercent Change From Baseline in Body Weight at Week 72
measured Baseline and Week 72
Participants Achieving ≥ 5% Reduction in Body Weight From Baseline at Week 72
measured Baseline and Week 72
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed